Development of asthma therapy with rAAV-mediated AMCase shRNA
US7851616B2 · kind B2 · utility
0Cited by
1References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 4, 2008 |
| Grant date | Dec 14, 2010 |
| Priority date | — |
| Expiry date | Dec 4, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/531
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides small interfering RNA (siRNA) and their carriers that could treat asthma in mammalian through inhibiting acidic mammalian chitinase (AMCase) gene expression. The invention further provides a composition comprising siRNA of the present invention and a carrier. The invention also provides a method for treating asthma of a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.